Revvity Inc (RVTY)

Industry Diagnostics & Research


This stock can be held in an Investment ISA and an Investment Account
Sell

$85.70

Buy

$100.00

arrow-down$-1.79 (-1.82%)

Prices updated at 13 May 2025, 22:59 EDT
| Prices minimum 15 mins delay
|
Prices in USD

PerkinElmer Inc is a diagnostics company that provides instruments, consumables, and services to biomedical, chemical and to general industrial markets. It operates in two segments namely Discovery and Analytical Solutions and Diagnostics.

Most recent dividend payment

0.070
Cash Dividend
18 Jul 2025
24 Apr 2025
18 Jul 2025
08 Aug 2025

Total dividend yield

Created with Highcharts 7.2.2Total yield (%)Total yield (%)202120222023202420250246

Dividend history and forecast data table

YearDividend per shareDividend growth (%)
20250.2100-
20240.2800-
20230.2800-
20220.2800-
20210.2800-
20200.2800-
20190.2800-
20180.2800-
20170.2800-
20160.2800-

Total dividend yield data table

Dividend yield (%)Buyback yield (%)
20250.304.59
20240.251.41
20230.262.92
20220.200.32
20210.140.29
20200.200.04
20190.290.54
20180.360.06
20170.380.05
20160.542.66

Dividend per share

Created with Highcharts 7.2.2Dividend per shareDividend per share2021202220232024202500.10.20.3

% of earnings paid to shareholders

Created with Highcharts 7.2.2Payout ratio (%)Payout ratio (%)2021202220232024202505101520

Dividend per share data table

YearDividend per share
20250.2100
20240.2800
20230.2800
20220.2800
20210.2800
20200.2800
20190.2800
20180.2800
20170.2800
20160.2800

% of earnings paid to shareholders data table

YearPayout ratio (%)
202511.58
202413.40
202316.47
20225.46
20212.79
20207.59
201913.33
201824.56
201711.97
201613.21
Latest Financial Report as of 12 May 2025
Dividend amount and dividend per share are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.